Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 14 trades.If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 42% with bearish.From the overall spotted trades, 5 are puts, for a total amount of $180,802 and 9, calls, for a total amount of $512,400.Projected Price TargetsAnalyzing the Volume and Open Interest in these cont ...

Key TakeawaysModerna (MRNA) received a positive CHMP opinion for its mCOMBRIAX vaccine, the world’s first combination flu and COVID-19 shot recommended for authorization.Blackstone (BX) and Brookfield (BN) have emerged as lead bidders for a €8 billion unit of Volkswagen (VOW3), highlighting intense private equity interest in industrial divestments.Kazakhstan is significantly shifting its energy logistics, targeting 2.5 million tons of oil exports to Germany in 2026 while maintaining a 65 million ton flow vi ...

Group 1 - The recommendation from regulators facilitates the approval process for the shot in the European Union [1] - The company is currently under scrutiny in the United States [1]

Group 1 - The European Medicines Agency has recommended granting marketing authorization for Moderna's mCombriax, making it the first combined vaccine for COVID-19 and seasonal influenza for individuals aged 50 and older [1] - The vaccine utilizes messenger RNA technology, which has been pivotal in the development of COVID-19 vaccines [1] Group 2 - The approval of mCombriax represents a significant advancement in public health, potentially simplifying vaccination processes for older populations [1] - This development may enhance Moderna's market position and revenue potential in the vaccine sector [1]

Moderna公司：新冠 流感疫苗获得欧盟监管机构推荐。 ...

Moderna (NASDAQ: MRNA) soared into the spotlight during the pandemic thanks to its mRNA technology and its rapid development of a coronavirus vaccine. But it's those two elements that have weighed on the stock in more recent times: The U.S. last year ended about $500 million in funding for mRNA vaccine development. And the coronavirus vaccine, facing lower demand, is no longer delivering the same levels of revenue that it did at its peak. The company has had its ups -- the approval of its respiratory sync ...

Piper Sandler将Moderna的目标价从63美元上调至69美元，维持"增持"评级。(格隆汇) ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 22 trades.If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 36% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $774,679 and 18, calls, for a total amount of $1,215,014.What's The Price Target?Taking into account the Volume and Open Interest ...

Moderna (NASDAQ: MRNA) became a household name during the coronavirus pandemic. There's a good reason for that: Its mRNA technology enabled the rapid development of a vaccine. The financial benefit of that success for Moderna was huge, but what comes next? Moderna hits a home run The onset of the COVID-19 pandemic was a global event and a material shock to the world's healthcare system. Moderna used its mRNA technology to help develop a vaccine in record time. The company's reward was a massive revenue sp ...

Group 1: Laffont's Investment Strategy - Billionaire Philippe Laffont, founder of Coatue Management, oversees $39 billion in 13F securities, primarily investing in technology stocks, with Taiwan Semiconductor Manufacturing as his largest holding at over 6.5% of his portfolio [1] - In the fourth quarter of the previous year, Laffont sold his entire position in CoreWeave, which had been a significant AI stock with triple-digit revenue growth [2][9] - Laffont's recent investment in Moderna, a biotech stock that has struggled but saw a nearly 50% increase in January, indicates a shift towards potential growth opportunities [3][12] Group 2: CoreWeave and Moderna - CoreWeave, which Laffont sold, had made up more than 2.2% of his portfolio and had seen an 80% increase since its IPO [8][9] - Moderna, which Laffont purchased 200,000 shares of, represents a very small position at 0.01% of his portfolio, but the company is focusing on long-term success through cost-cutting and expanding its vaccine offerings [10][11] - Moderna's stock has lost over 70% in the past three years, but its pipeline includes candidates in late-stage development, suggesting potential for recovery and growth in the future [10][14]